Following IPO, Fluidigm Reports Double-Digit Revenue Growth for Q4, FY'10
March 10, 2011
Following IPO, Fluidigm Reports Double-Digit Revenue Growth for Q4, FY'10
The company reported a 36 percent increase in fourth-quarter revenues and 32 percent increase in yearly revenues; and CEO Gajus Worthington provided an update regarding the uptake of Fludigm's newest instruments and the company's fledgling diagnostics play.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Amid Plans for $86.3M IPO, Fluidigm Discloses Novartis Prenatal Dx Deal
December 9, 2010 / PCR Insider - Product Watch
May 20, 2010 / PCR Insider - Fluidigm Names Scandinavian Distributor
February 2, 2012 / PCR Insider - Fluidigm Taps Research Instruments as Distributor in Singapore, Thailand
October 20, 2011 / PCR Insider - Fluidigm Taps Eisenberg Brothers as Israeli Distributor
February 24, 2011 / PCR Insider